{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T22:28:48Z","timestamp":1785364128055,"version":"3.55.0"},"reference-count":43,"publisher":"BMJ","issue":"10","license":[{"start":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:00:00Z","timestamp":1759449600000},"content-version":"unspecified","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by\/3.0\/igo\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Glob Health"],"accepted":{"date-parts":[[2025,8,28]]},"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:p>\n                    Malaria treatment failures associated with reduced efficacy of chloroquine (CQ) and amodiaquine (AQ) antimalarial drugs emerged in Rwanda during the 1980s, prompting the policy shift towards adopting artemisinin-based combination therapies in 2006 as an alternative. However, recent findings from malaria surveillance and therapeutic efficacy studies have revealed a countrywide increase in antimalarial drug resistance. Particularly, artemether-lumefantrine (AL) efficacy has significantly decreased, probably due to the emergence of\n                    <jats:italic>Plasmodium falciparum<\/jats:italic>\n                    (\n                    <jats:italic>Pf<\/jats:italic>\n                    ) genomic mutations. To mitigate the current drug resistance, Rwanda has adopted targeted multiple first-line therapies. Through the national malaria control program, antimalarial drugs were deployed in accordance with the reported resistance profile. A significant rise in\n                    <jats:italic>Pfkelch13<\/jats:italic>\n                    mutations, particularly A675V associated with AL resistance, was mainly reported in the western region; therefore, artesunate-pyronaridine was recommended. Dihydroartemisinin-piperaquine was considered in eastern and central regions, where\n                    <jats:italic>R561H<\/jats:italic>\n                    mutations were predominant. On the contrary, AL was maintained in the southern region, where the prevalence of the\n                    <jats:italic>R561H<\/jats:italic>\n                    mutation was low. Insights from this data-driven model will inform its extension to other malaria-endemic countries facing emerging\n                    <jats:italic>Pf<\/jats:italic>\n                    genetic diversity.\n                  <\/jats:p>","DOI":"10.1136\/bmjgh-2025-020884","type":"journal-article","created":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T06:40:25Z","timestamp":1759473625000},"page":"e020884","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Strategies for mitigating emerging artemisinin-based antimalarial drug resistance in Rwanda: a promising approach for managing therapies in malaria-endemic countries"],"prefix":"10.1136","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4180-442X","authenticated-orcid":false,"given":"Claude Mambo","family":"Muvunyi","sequence":"first","affiliation":[{"name":"Rwanda Biomedical Center, Kigali, Rwanda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9348-0936","authenticated-orcid":false,"given":"Pierre","family":"Gashema","sequence":"additional","affiliation":[{"name":"Africa Centres for Disease Control and Prevention, Addis Ababa, Ethiopia"},{"name":"Repolicy Research Centre, Kigali, Rwanda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimable","family":"Mbituyumuremyi","sequence":"additional","affiliation":[{"name":"Rwanda Biomedical Center, Kigali, Rwanda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0236-7776","authenticated-orcid":false,"given":"Patrick Gad","family":"IRADUKUNDA","sequence":"additional","affiliation":[{"name":"Repolicy Research Centre, Kigali, Rwanda"},{"name":"Quality Management Division, Rwanda FDA, Kigali, Kigali City, Rwanda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6314-7374","authenticated-orcid":false,"given":"Emmanuel Edwar","family":"Siddig","sequence":"additional","affiliation":[{"name":"Africa Centres for Disease Control and Prevention, Addis Ababa, Ethiopia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Damascene","family":"Niyonzima","sequence":"additional","affiliation":[{"name":"Rwanda Biomedical Center, Kigali, Rwanda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Hakizimana","sequence":"additional","affiliation":[{"name":"Rwanda Biomedical Center, Kigali, Rwanda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noella","family":"Umulisa","sequence":"additional","affiliation":[{"name":"Jhpiego Kigali, Rwanda, Kigali, Rwanda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdisalan Mohamed","family":"Noor","sequence":"additional","affiliation":[{"name":"Harvard University, Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6554-6194","authenticated-orcid":false,"given":"Jules","family":"Mugabo Semahore","sequence":"additional","affiliation":[{"name":"World Health Organization Kigali, Rwanda, Kigali, Rwanda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Tuyishime","sequence":"additional","affiliation":[{"name":"Rwanda Biomedical Center, Kigali, Rwanda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0944-5404","authenticated-orcid":false,"given":"Jean de Dieu","family":"HARELIMANA","sequence":"additional","affiliation":[{"name":"Rwanda Biomedical Center, Kigali, Rwanda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanne","family":"Umuhire","sequence":"additional","affiliation":[{"name":"Rwanda Biomedical Center, Kigali, Rwanda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvan","family":"Butera","sequence":"additional","affiliation":[{"name":"Republic of Rwanda Ministry of Health, Kigali, Kigali City, Rwanda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabin","family":"Nsanzimana","sequence":"additional","affiliation":[{"name":"Republic of Rwanda Ministry of Health, Kigali, Kigali City, Rwanda"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,10,2]]},"reference":[{"key":"2025120102351533000_10.10.e020884.1","unstructured":"World malaria report 2024. Available: https:\/\/www.who.int\/teams\/global-malaria-programme\/reports\/world-malaria-report-2024"},{"key":"2025120102351533000_10.10.e020884.2","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro2239"},{"key":"2025120102351533000_10.10.e020884.3","unstructured":"World Health Organization . Global report on antimalarial drug efficacy and drug resistance: 2000-2010. 2010."},{"key":"2025120102351533000_10.10.e020884.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.trstmh.2006.06.010"},{"key":"2025120102351533000_10.10.e020884.5","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12936-024-04848-8","article-title":"Emergence of Plasmodium falciparum strains with artemisinin partial resistance in East Africa and the Horn of Africa: is there a need to panic?","volume":"23","author":"Assefa","year":"2024","journal-title":"Malar J"},{"key":"2025120102351533000_10.10.e020884.6","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00142-0"},{"key":"2025120102351533000_10.10.e020884.7","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-024-04981-4"},{"key":"2025120102351533000_10.10.e020884.8","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1093\/infdis\/jiae475","article-title":"High Frequency of Artemisinin Partial Resistance Mutations in the Great Lakes Region Revealed Through Rapid Pooled Deep Sequencing","volume":"231","author":"Wernsman Young","year":"2025","journal-title":"J Infect Dis"},{"key":"2025120102351533000_10.10.e020884.9","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofad149","article-title":"Examining the Early Distribution of the Artemisinin-Resistant Plasmodium falciparum kelch13 R561H Mutation in Areas of Higher Transmission in Rwanda","volume":"10","author":"Kirby","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"2025120102351533000_10.10.e020884.10","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1005-2"},{"key":"2025120102351533000_10.10.e020884.11","unstructured":"Multiple first-line therapies as part of the response to antimalarial drug resistance: an implementation guide. Drug Resist."},{"key":"2025120102351533000_10.10.e020884.12","article-title":"Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria","volume":"2014","author":"Zani","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"2025120102351533000_10.10.e020884.13","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.20-0185"},{"key":"2025120102351533000_10.10.e020884.14","doi-asserted-by":"crossref","DOI":"10.1016\/0035-9203(89)90262-9","article-title":"Evolution of resistance of Plasmodium falciparum to antimalarial drugs in Rwanda, 1985-1987","volume":"83","author":"Garcia-Vidal","year":"1989","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"2025120102351533000_10.10.e020884.15","doi-asserted-by":"crossref","unstructured":"Gasc\u00f3n J , Soldevila M , Merlos A , et al . FALCIPARUM MALARIA IN RWANDA. The Lancet 1985;326. doi:10.1016\/S0140-6736(85)90944-4","DOI":"10.1016\/S0140-6736(85)90944-4"},{"key":"2025120102351533000_10.10.e020884.16","doi-asserted-by":"crossref","first-page":"244","DOI":"10.4269\/ajtmh.1988.38.244","article-title":"Amodiaquine and Sulfadoxine-Pyrimethamine as Treatment for Chloroquine-Resistant Plasmodium falciparum in Rwanda","volume":"38","author":"Deloron","year":"1988","journal-title":"Am J Trop Med Hyg"},{"key":"2025120102351533000_10.10.e020884.17","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1046\/j.1365-3156.2001.00799.x","article-title":"Monitoring antimalarial drug resistance within National Malaria Control Programmes: the EANMAT experience","volume":"6","year":"2001","journal-title":"Tropical Med Int Health"},{"key":"2025120102351533000_10.10.e020884.18","doi-asserted-by":"crossref","first-page":"743","DOI":"10.4269\/ajtmh.2003.68.743","article-title":"Efficacy of amodiaquine alone and combined with sulfadoxine-pyrimethamine and of sulfadoxine pyrimethamine combined with artesunate","volume":"68","author":"Rwagacondo","year":"2003","journal-title":"Am J Trop Med Hyg"},{"key":"2025120102351533000_10.10.e020884.19","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3156.2004.01316.x"},{"key":"2025120102351533000_10.10.e020884.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.trstmh.2006.01.001"},{"key":"2025120102351533000_10.10.e020884.21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0006358","article-title":"Safety and efficacy of dihydroartemisinin-piperaquine in falciparum malaria: a prospective multi-centre individual patient data analysis","volume":"4","author":"Zwang","year":"2009","journal-title":"PLoS ONE"},{"key":"2025120102351533000_10.10.e020884.22","doi-asserted-by":"crossref","DOI":"10.1186\/1475-2875-8-203","article-title":"Efficacy of artesunate-amodiaquine for treating uncomplicated falciparum malaria in sub-Saharan Africa: a multi-centre analysis","volume":"8","author":"Zwang","year":"2009","journal-title":"Malar J"},{"key":"2025120102351533000_10.10.e020884.23","doi-asserted-by":"crossref","unstructured":"Sagara I , Rulisa S , Mbacham W , et al . Efficacy and safety of a fixed dose artesunate-sulphamethoxypyrazine-pyrimethamine compared to artemether-lumefantrine for the treatment of uncomplicated falciparum malaria across Africa: a randomized multi-centre trial. Malar J 2009;8. doi:10.1186\/1475-2875-8-63","DOI":"10.1186\/1475-2875-8-63"},{"key":"2025120102351533000_10.10.e020884.24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001119","article-title":"A head-to-head comparison of four artemisinin-based combinations for treating uncomplicated malaria in African children: a randomized trial","volume":"8","year":"2011","journal-title":"PLoS Med"},{"key":"2025120102351533000_10.10.e020884.25","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00498-09"},{"key":"2025120102351533000_10.10.e020884.26","unstructured":"Lucchi N , Umulisa N , Harerimana JM , et al . Uncorrected Efficacy of artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum infection in Rwanda. 2022."},{"key":"2025120102351533000_10.10.e020884.27","unstructured":"Subregional networks of antimalaria drug efficacy and resistance in eastern africa and horn of Africa countries. Available: https:\/\/www.who.int\/publications\/i\/item\/9789240106758 [Accessed 10 Apr 2025]."},{"key":"2025120102351533000_10.10.e020884.28","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-33873-x","article-title":"Decreased susceptibility of Plasmodium falciparum to both dihydroartemisinin and lumefantrine in northern Uganda","volume":"13","author":"Tumwebaze","year":"2022","journal-title":"Nat Commun"},{"key":"2025120102351533000_10.10.e020884.29","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1093\/infdis\/jiaf068","article-title":"Prevalence of Plasmodium falciparum Drug Resistance Markers pfcrt K76T and pfaat1 S258L in Southern Rwanda, 2010 to 2023","volume":"232","author":"Schallenberg","year":"2025","journal-title":"J Infect Dis"},{"key":"2025120102351533000_10.10.e020884.30","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiab352"},{"key":"2025120102351533000_10.10.e020884.31","doi-asserted-by":"publisher","DOI":"10.3201\/eid2701.203527"},{"key":"2025120102351533000_10.10.e020884.32","doi-asserted-by":"crossref","unstructured":"Meier-Scherling CPG , Watson OJ , Asua V , et al . Selection of artemisinin partial resistance Kelch13 mutations in Uganda in 2016-22 was at a rate comparable to that seen previously in South-East Asia. medRxiv 2023. doi:10.1101\/2024.02.03.24302209","DOI":"10.2139\/ssrn.4716749"},{"key":"2025120102351533000_10.10.e020884.33","doi-asserted-by":"crossref","unstructured":"Juliano JJ , Giesbrecht DJ , Simkin A , et al . Country wide surveillance reveals prevalent artemisinin partial resistance mutations with evidence for multiple origins and expansion of high level sulfadoxine-pyrimethamine resistance mutations in northwest tanzania. medRxiv [Preprint]. doi:10.1101\/2023.11.07.23298207","DOI":"10.1101\/2023.11.07.23298207"},{"key":"2025120102351533000_10.10.e020884.34","unstructured":"Rwanda_Malaria_NSP_Mid_Term_Report_2023.pdf. 2025. Available: https:\/\/www.rbc.gov.rw\/fileadmin\/user_upload\/report_2024\/Rwanda_Malaria_NSP_Mid_Term_Report_2023.pdf"},{"key":"2025120102351533000_10.10.e020884.35","unstructured":"MOPDD_Annual_Report_FY2023-2024.pdf. 2025. Available: https:\/\/rbc.gov.rw\/fileadmin\/user_upload\/report_2024\/malaria_2025\/MOPDD_Annual_Report_FY2023-2024.pdf"},{"key":"2025120102351533000_10.10.e020884.36","unstructured":"RBC: RBC and Zipline introduce drone delivery of Malaria medicines. 2025 Available: https:\/\/rbc.gov.rw\/media\/details?tx_news_pi1%5Baction%5D=detail&tx_news_pi1%5Bcontroller%5D=News&tx_news_pi1%5Bnews%5D=1113&cHash=af33f97230085d91c6a3bbe5b1cdfbc4"},{"key":"2025120102351533000_10.10.e020884.37","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(12)70241-4"},{"key":"2025120102351533000_10.10.e020884.38","unstructured":"Strategy to respond to antimalarial drug resistance in Africa. 1st edn. World Health Organization, 2022."},{"key":"2025120102351533000_10.10.e020884.39","doi-asserted-by":"crossref","DOI":"10.1186\/s12936-021-03740-z","article-title":"Implementation and success factors from Thailand\u2019s 1-3-7 surveillance strategy for malaria elimination","volume":"20","author":"Lertpiriyasuwat","year":"2021","journal-title":"Malar J"},{"key":"2025120102351533000_10.10.e020884.40","doi-asserted-by":"crossref","DOI":"10.1186\/s12936-016-1200-2","article-title":"Evidence of successful malaria case management policy implementation in Cambodia: results from national ACTwatch outlet surveys","volume":"15","author":"Novotny","year":"2016","journal-title":"Malar J"},{"key":"2025120102351533000_10.10.e020884.41","doi-asserted-by":"crossref","DOI":"10.1186\/1475-2875-8-63","article-title":"Efficacy and safety of a fixed dose artesunate-sulphamethoxypyrazine-pyrimethamine compared to artemether-lumefantrine for the treatment of uncomplicated falciparum malaria across Africa: a randomized multi-centre trial","volume":"8","author":"Sagara","year":"2009","journal-title":"Malar J"},{"key":"2025120102351533000_10.10.e020884.42","doi-asserted-by":"crossref","unstructured":"The Four Artemisinin-Based Combinations (4ABC) Study Group . n.d. A Head-to-Head Comparison of Four Artemisinin-Based Combinations for Treating Uncomplicated Malaria in African Children: A Randomized Trial. PLoS Med 8:e1001119. doi:10.1371\/journal.pmed.1001119","DOI":"10.1371\/journal.pmed.1001119"},{"key":"2025120102351533000_10.10.e020884.43","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1093\/trstmh\/trz009","article-title":"Efficacy of artemether-lumefantrine versus dihydroartemisinin-piperaquine for the treatment of uncomplicated malaria among children in Rwanda: an open-label, randomized controlled trial","volume":"113","author":"Uwimana","year":"2019","journal-title":"Trans R Soc Trop Med Hyg"}],"container-title":["BMJ Global Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjgh-2025-020884","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T10:35:40Z","timestamp":1764585340000},"score":1,"resource":{"primary":{"URL":"https:\/\/gh.bmj.com\/lookup\/doi\/10.1136\/bmjgh-2025-020884"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":43,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10,2]]},"published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1136\/bmjgh-2025-020884"],"URL":"https:\/\/doi.org\/10.1136\/bmjgh-2025-020884","relation":{},"ISSN":["2059-7908"],"issn-type":[{"value":"2059-7908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10]]}}}